No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALLK Allakos
- 1.250
- +0.040+3.31%
Close May 31 16:00 ET
- 1.231
- -0.019-1.55%
Post 18:03 ET
110.68MMarket Cap-508P/E (TTM)
1.260High1.190Low368.49KVolume1.220Open1.210Pre Close453.56KTurnover0.62%Turnover RatioLossP/E (Static)88.54MShares5.64052wk High1.06P/B73.83MFloat Cap0.98052wk Low--Dividend TTM59.07MShs Float157.980Historical High--Div YieldTTM5.78%Amplitude0.980Historical Low1.230Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
Express News | Allakos Says First Patient Has Been Dosed In Phase 1 Trial Of AK006 In Chronic Spontaneous Urticaria
Express News | Allakos Inc - Top-Line Phase 1 Csu Results Expected at Year End 2024
Express News | Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Comments
$Allakos(ALLK.US$ Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria! Top-Line Phase 1 Csu Results Expected at Year End 2024
1
$Allakos(ALLK.US$ mark my words buyout rumors or news in 2-3 months
$Allakos(ALLK.US$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30
SEC announcement
·
01/29 17:30
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg